- Home
- LRE vs MRKR Comparison
LRE vs MRKR Comparison
Compare LRE & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- MRKR
- Stock Information
- Founded
- LRE 2001
- MRKR N/A
- Country
- LRE Japan
- MRKR United States
- Employees
- LRE N/A
- MRKR N/A
- Industry
- LRE
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- MRKR Health Care
- Exchange
- LRE Nasdaq
- MRKR Nasdaq
- Market Cap
- LRE 17.6M
- MRKR 19.1M
- IPO Year
- LRE 2023
- MRKR N/A
- Fundamental
- Price
- LRE $1.80
- MRKR $1.53
- Analyst Decision
- LRE
- MRKR Strong Buy
- Analyst Count
- LRE 0
- MRKR 3
- Target Price
- LRE N/A
- MRKR $13.17
- AVG Volume (30 Days)
- LRE 15.3K
- MRKR 100.8K
- Earning Date
- LRE 01-01-0001
- MRKR 08-13-2025
- Dividend Yield
- LRE N/A
- MRKR N/A
- EPS Growth
- LRE N/A
- MRKR N/A
- EPS
- LRE 0.29
- MRKR N/A
- Revenue
- LRE $117,804,154.00
- MRKR $5,696,123.00
- Revenue This Year
- LRE N/A
- MRKR N/A
- Revenue Next Year
- LRE N/A
- MRKR $11.28
- P/E Ratio
- LRE $6.19
- MRKR N/A
- Revenue Growth
- LRE 8.82
- MRKR 71.53
- 52 Week Low
- LRE $1.10
- MRKR $0.95
- 52 Week High
- LRE $2.49
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- LRE 54.60
- MRKR 51.60
- Support Level
- LRE $1.64
- MRKR $1.42
- Resistance Level
- LRE $2.11
- MRKR $1.55
- Average True Range (ATR)
- LRE 0.14
- MRKR 0.13
- MACD
- LRE -0.01
- MRKR -0.02
- Stochastic Oscillator
- LRE 24.49
- MRKR 13.23
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.